DSAEK rapidly restores corneal clarity in young CHED patients

Article

Descemet-stripping automated endothelial keratoplasty (DSAEK) efficiently restores corneal clarity with minimal complications in young congenital hereditary endothelial dystrophy (CHED) patients

Descemet-stripping automated endothelial keratoplasty (DSAEK) efficiently restores corneal clarity with minimal complications in young congenital hereditary endothelial dystrophy (CHED) patients, according to a study published in the Archives of Ophthalmology.

A team led by Dr Massimo Busin, Villa Serena Hospital, Forlí, Italy, examined the medical records of 15 eyes of 8 CHED patients who underwent DSAEK. A detailed ophthalmic examination of all patients was conducted preoperatively and at each postoperative visit. All patients underwent standard DSAEK, except in patients younger than 12 months. These patients didn't have their Descemet membrane removed.

The mean patient age was 9 years and the average follow-up period was 15.9 months. Graft detachment was found in 4 cases and was treated by rebubbling.

Within 1 week after surgery all corneas were clear. Preoperatively, six eyes were able to fix and follow and 3 eyes could fix and follow 1 week postoperatively. Preoperative best-corrected visual acuity was recorded as 20/200 or less in 6 eyes. Best-corrected visual acuity of 20/40 or better was achieved postoperatively.

The study advises conducting DSAEK at an earlier age in order to provide improved visual development and possibly prevent amblyopia.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.